From drugs to biomaterials: a review of emerging therapeutic strategies for intervertebral disc inflammation

Front Cell Infect Microbiol. 2024 Jan 30:14:1303645. doi: 10.3389/fcimb.2024.1303645. eCollection 2024.

Abstract

Chronic low back pain (LBP) is an increasingly prevalent issue, especially among aging populations. A major underlying cause of LBP is intervertebral disc degeneration (IDD), often triggered by intervertebral disc (IVD) inflammation. Inflammation of the IVD is divided into Septic and Aseptic inflammation. Conservative therapy and surgical treatment often fail to address the root cause of IDD. Recent advances in the treatment of IVD infection and inflammation range from antibiotics and small-molecule drugs to cellular therapies, biological agents, and innovative biomaterials. This review sheds light on the complex mechanisms of IVD inflammation and physiological and biochemical processes of IDD. Furthermore, it provides an overview of recent research developments in this area, intending to identify novel therapeutic targets and guide future clinical strategies for effectively treating IVD-related conditions.

Keywords: infection; inflammation; intervertebral disc; low back pain; treatment.

Publication types

  • Review

MeSH terms

  • Humans
  • Inflammation / complications
  • Intervertebral Disc Degeneration* / drug therapy
  • Intervertebral Disc Degeneration* / etiology
  • Intervertebral Disc* / physiology

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.